Medicare Drug Price Negotiations Cut Costs for 15 Key Medications
The Trump administration has implemented new lower Medicare prices for 15 prescription drugs as part of the Medicare drug price negotiation program initiated under the Inflation Reduction Act. This round focused on high-cost drugs, including widely used cancer and diabetes medications, inhalers, and GLP-1 drugs, representing some of the largest expenditures for Medicare. The negotiated prices apply to the government’s payment rates, potentially reducing Medicare spending by $12 billion compared to the previous year.